

International Textbook of Diabetes Mellitus, 4th Ed., Chapter 29 - Immunopathogenesis of Type 1 Diabetes in Western Society

References

1. Knip M, Simell O: Environmental triggers of type 1 diabetes. Cold Spring Harbor Perspectives in Medicine 2012;2(7):a007690.
2. Roep BO, Peakman M: Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harbor Perspectives in Medicine 2012; 2(4):a007781.
3. Yu L, Boulware DC, Beam CA, et al.: Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012;35(6):1213–1218. 450 Chapter 29
4. Maahs DM, West NA, Lawrence JM, et al.: Epidemiology of type 1 diabetes. Endocrinology Metabolism Clinics of North America 2010;39(3):481–497.
5. Barker JM, Barriga KJ, Yu L, et al.: Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Journal of Clinical Endocrinology & Metabolism 2004;89(8):3896–3902.
6. Leslie RD, Kolb H, Schloot NC, et al.: Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes/Metabolism Research Reviews 2008;24(7):511–519.
7. Grant SF, Hakonarson H, Schwartz S: Can the genetics of type 1 and type 2 diabetes shed light on the genetics of latent autoimmune diabetes in adults? Endocrine Reviews 2010;31(2):183–193.
8. Patterson CC, Gyurus E, Rosenbauer J, et al.: Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase. Diabetologia 2012;55(8):2142–2147.
9. Songini M, Lombardo C: The Sardinian way to type 1 diabetes. Journal of Diabetes Science and Technology 2010;4(5):1248–1255.
10. Dahlquist GG, Nystrom L, Patterson CC: Incidence of type 1 diabetes in Sweden among individuals aged 0–34 years, 1983–2007: an analysis of time trends. Diabetes Care 2011;34(8):1754–1759.
11. Redondo MJ, Jeffrey J, Fain PR, et al.: Concordance for islet autoimmunity among monozygotic twins. New England Journal of Medicine 2008;359(26):2849–2850.
12. Pociot F, Akolkar B, Concannon P, et al.: Genetics of type 1 diabetes: what's next? Diabetes 2010;59(7):1561–1571.
13. Cooper JD, Howson JM, Smyth D, et al.: Confirmation of novel type 1 diabetes risk loci in families. Diabetologia 2012;55(4):996–1000.
14. Rakyan VK, Beyan H, Down TA, et al.: Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genetics 2011;7(9):e1002300.
15. Macfarlane AJ, Strom A, Scott FW: Epigenetics: deciphering how environmental factors may modify autoimmune type 1 diabetes. Mammalian Genome 2009;20(9–10):624–632.
16. Erlich H, Valdes AM, Noble J, et al.: HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008;57(4):1084–1092.
17. van Lummel M, van Veelen PA, Zaldumbide A, et al.: Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire. The Journal of Biological Chemistry 2012;287(12):9514–9524.
18. Pugliese A, Kawasaki E, Zeller M, et al.: Sequence analysis of the diabetes-protective human leukocyte antigen-DQB1*0602 allele in unaffected, islet cell

- antibody-positive first-degree relatives and in rare patients with type 1 diabetes. *Journal of Clinical Endocrinology & Metabolism* 1999;84(5):1722–1728.
19. Nejentsev S, Howson JM, Walker NM, et al.: Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. *Nature* 2007;450(7171):887–892.
 20. Rich SS, Akolkar B, Concannon P, et al.: Results of the MHC fine mapping workshop. *Diabetes, Obesity and Metabolism* 2009;11(Suppl 1):108–109.
 21. Derbinski J, Kyewski B: How thymic antigen presenting cells sample the body's self-antigens. *Current Opinion in Immunology* 2010;22(5):592–600.
 22. Anderson MS, Venanzi ES, Klein L, et al.: Projection of an immunological self shadow within the thymus by the aire protein. *Science* 2002;298(5597):1395–1401.
 23. Pugliese A, Brown D, Garza D, et al.: Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. *Journal of Clinical Investigation* 2001;107(5):555–564.
 24. Gardner JM, DeVoss JJ, Friedman RS, et al.: Deletional tolerance mediated by extrathymic Aire-expressing cells. *Science* 2008;321(5890):843–847.
 25. Hubert FX, Kinkel SA, Davey GM, et al.: Aire regulates the transfer of antigen from mTECs to dendritic cells for induction of thymic tolerance. *Blood* 2011;118(9):2462–2472.
 26. Fan Y, Rudert WA, Grupillo M, et al.: Thymus-specific deletion of insulin induces autoimmune diabetes. *EMBO Journal* 2009;28(18):2812–2824.
 27. Pugliese A, Zeller M, Fernandez AJ, et al.: The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDD2 susceptibility locus for type 1 diabetes. *Nature Genetics* 1997;15(3):293–297.
 28. Vafiadis P, Bennett ST, Todd JA, et al.: Insulin expression in the thymus is modulated by INS VNTR alleles at the IDDM2 locus. *Nature Genetics* 1997;15:289–292.
 29. Sabater L, Ferrer-Francesch X, Sospedra M, et al.: Insulin alleles and autoimmune regulator (AIRE) gene expression both influence insulin expression in the thymus. *Journal of Autoimmunology* 2005;25(4):312–318.
 30. Noso S, Kataoka K, Kawabata Y, et al.: Insulin transactivator MafA regulates intrathymic expression of insulin and affects susceptibility to type 1 diabetes. *Diabetes* 2010;59(10):2579–2587.
 31. Durinovic-Bello I, Wu RP, Gersuk VH, et al.: Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. *Genes & Immunity* 2010;11(2):188–193.
 32. Diez J, Park Y, Zeller M, et al.: Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. *Diabetes* 2001;50(4):895–900.
 33. Dogra RS, Vaidyanathan P, Prabakar KR, et al.: Alternative splicing of G6PC2, the gene coding for the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), results in differential expression in human thymus and spleen compared with pancreas. *Diabetologia* 2006;49(5):953–957.
 34. Vang T, Congia M, Macis MD, et al.: Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. *Nature Genetics* 2005;37(12):1317–1319.
 35. Schubert DA, Gordo S, Sabatino JJ, Jr., et al.: Self-reactive human CD4 T cell clones form unusual immunological synapses. *Journal of Experimental Medicine* 2012;209(2):335–352.

36. Yang XY, Levi D, Ounissi-Benkalha H, et al.: Screening for novel lead compounds increasing insulin expression in medullary thymic epithelial cells. *European Journal of Pharmacology* 2012; 688(1–3):84–89.
37. Suri A, Walters JJ, Gross ML, Unanue ER: Natural peptides selected by diabetogenic DQ8 and murine I-A(g7)molecules show common sequence specificity. *Journal of Clinical Investigation* 2005;115(8):2268–2276.
38. Mohan JF, Petzold SJ, Unanue ER: Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. *Journal of Experimental Medicine* 2011;208(12): 2375–2383.
39. Nakayama M, Abiru N, Moriyama H, et al.: Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. *Nature* 2005;435(7039):220–223.
40. Bulek AM, Cole DK, Skowera A, et al.: Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. *Nature Immunology* 2012;13(3):283–289.
41. Michels AW, Ostrov DA, Zhang L, et al.: Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. *Journal of Immunology* 2011;187(11):5921–5930.
42. Poliani PL, Kisand K, Marrella V, et al.: Human peripheral lymphoid tissues contain autoimmune regulator-expressing dendritic cells. *The American Journal of Pathology* 2010;176(3):1104–1112.
43. Grupillo M, Gualtierotti G, He J, et al.: Essential roles of insulin expression in Aire+ tolerogenic dendritic cells in maintaining peripheral self-tolerance of islet beta-cells. *Cell Immunology* 2012;273(2):115–123.
44. Cohen JN, Guidi CJ, Tewalt EF, et al.: Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. *Journal of Experimental Medicine* 2010;207(4):681–688.
45. Fletcher AL, Lukacs-Kornek V, Reynoso ED, et al.: Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. *Journal of Experimental Medicine* 2010;207(4):689–697.
46. Kodama K, Butte AJ, Creusot RJ, et al.: Tissue- and age-specific changes in gene expression during disease induction and progression in NOD mice. *Clinical Immunology* 2008;129(2):195–201.
47. Yip L, Su L, Sheng D, et al.: Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. *Nature Immunology* 2009;10(9):1026–1033.
48. Jeker LT, Bour-Jordan H, Bluestone JA: Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. *Cold Spring Harbor Perspectives in Medicine* 2012;2(3):a007807.
49. Buckner JH: Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. *Nature Reviews Immunology* 2010;10(12):849–859.
50. Ferraro A, Socci C, Stabilini A, et al.: Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. *Diabetes* 2011;60(11):2903–2913.
51. Rieck M, Arechiga A, Onengut-Gumuscu S, et al.: Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. *Journal of Immunology* 2007;179(7):4704–4710.
52. Menard L, Saadoun D, Isnardi I, et al.: The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. *Journal of Clinical Investigation* 2011;121(9):3635–3644.

53. Gerold KD, Zheng P, Rainbow DB, et al.: The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. *Diabetes* 2011;60(7):1955–1963.
54. Orban T, Bundy B, Becker DJ, et al.: Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. *Lancet* 2011;378(9789):412–419.
55. Wang J, Wicker LS, Santamaria P: IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity. *Seminars in Immunology* 2009;21(6):363–371.
56. Garg G, Tyler JR, Yang JH, et al.: Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. *Journal of Immunology* 2012;188(9):4644–4653.
57. Grinberg-Bleyer Y, Baeyens A, You S, et al.: IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. *Journal of Experimental Medicine* 2010;207(9):1871–1878.
58. Malek TR, Pugliese A: Low-dose IL-2 as a therapeutic agent for tolerance induction. *Immunotherapy* 2011;3(11):1281–1284.
59. Hermann R, Knip M, Veijola R, et al.: Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes: indication of an increased environmental pressure? *Diabetologia* 2003;46(3):420–425.
60. Gillespie KM, Bain SC, Barnett AH, et al.: The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. *Lancet* 2004;364(9446):1699–1700.
61. Furlanos S, Varney MD, Tait BD, et al.: The rising incidence of type 1 diabetes is accounted for by cases with lower risk human leukocyte antigen genotypes. *Diabetes Care* 2008;31(8): 1546–1549.
62. Vehik K, Hamman RF, Lezotte D, et al.: Trends in high-risk HLA susceptibility genes among Colorado youth with type 1 diabetes. *Diabetes Care* 2008;31(7):1392–1396.
63. Resic-Lindehammer S, Larsson K, Ortqvist E, et al.: Temporal trends of HLA genotype frequencies of type 1 diabetes patients in Sweden from 1986 to 2005 suggest altered risk. *Acta Diabetologica* 2008;45(4):231–235.
64. Stene LC, Rewers M: Immunology in the clinic review series; focus on type 1 diabetes and viruses: the enterovirus link to type 1 diabetes: critical review of human studies. *Clinical and Experimental Immunology* 2012;168(1):12–23.
65. Grieco FA, Sebastiani G, Spagnuolo I, et al.: Immunology in the clinic review series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. *Clinical and Experimental Immunology* 2012;168(1):24–29.
66. Viskari H, Knip M, Tauriainen S, et al.: Maternal enterovirus infection as a risk factor for type 1 diabetes in the exposed offspring. *Diabetes Care* 2012;35(6):1328–1332.
67. Jaidane H, Sane F, Hiar R, et al.: Immunology in the clinic review series; focus on type 1 diabetes and viruses: enterovirus, thymus and type 1 diabetes pathogenesis. *Clinical and Experimental Immunology* 2012;168(1):39–46.
68. Chistiakov DA: Interferon induced with helicase C domain 1 (IFIH1) and virus-induced autoimmunity: a review. *Viral Immunology* 2010;23(1):3–15.
69. Dotta F, Censini S, van Halteren AG, et al.: Coxsackie B4 virus infection of beta cells and natural killer cell insulinitis in recent-onset type 1 diabetic patients. *PNAS* 2007;104(12):5115–5120.

70. Richardson SJ, Willcox A, Bone AJ, et al.: The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. *Diabetologia* 2009;52(6):1143–1151.
71. Willcox A, Richardson SJ, Bone AJ, et al.: Immunohistochemical analysis of the relationship between islet cell proliferation and the production of the enteroviral capsid protein, VP1, in the islets of patients with recent-onset type 1 diabetes. *Diabetologia* 2011;54(9):2417–2420.
72. Mohan JF, Levisetti MG, Calderon B, et al.: Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. *Nature Immunology* 2010;11(4):350–354.
73. Mathis D, Vence L, Benoist C: beta-Cell death during progression to diabetes. *Nature* 2001;414(6865):792–798.
74. Honkanen J, Nieminen JK, Gao R, et al.: IL-17 immunity in human type 1 diabetes. *Journal of Immunology* 2010;185(3):1959–1967.
75. Kent SC, Chen Y, Bregoli L, et al.: Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. *Nature* 2005;435(7039):224–228.
76. Vendrame F, Pileggi A, Laughlin E, et al.: Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. *Diabetes* 2010;59(4): 947–957.
77. Kronenberg D, Knight RR, Estorninho M, et al.: Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. *Diabetes* 2012;61(7):1752–1759.
78. Coppieters KT, Dotta F, Amirian N, et al.: Demonstration of islet-autoreactive CD8 T cells in insulinitic lesions from recent onset and long-term type 1 diabetes patients. *Journal of Experimental Medicine* 2012;209(1):51–60.
79. Keenan HA, Sun JK, Levine J, et al.: Residual insulin production and pancreatic β -cell turnover after 50 years of diabetes: Joslin Medalist Study. *Diabetes* 2010;59(11):2846–2853.
80. Wang L, Lovejoy NF, Faustman DL: Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. *Diabetes Care* 2012;35(3): 465–470.
81. Meier JJ, Bhushan A, Butler AE, et al.: Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? *Diabetologia* 2005;48(11):2221–2228.
82. Jaeger C, Brendel MD, Eckhard M, Bretzel RG: Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. *Experimental and Clinical Endocrinology & Diabetes* 2000;108(5):328–333.
83. Hilbrands R, Huurman VA, Gillard P, et al.: Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. *Diabetes* 2009;58(10):2267–2276.
84. Monti P, Heninger AK, Bonifacio E: Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. *Current Diabetes Reports* 2009;9(2):113–118.
85. Fourlanos S, Narendran P, Byrnes GB, et al.: Insulin resistance is a risk factor for progression to type 1 diabetes. *Diabetologia* 2004;47(10):1661–1667.
86. Xu P, Cuthbertson D, Greenbaum C, et al.: Role of insulin resistance in predicting progression to type 1 diabetes. *Diabetes Care* 2007;30(9):2314–2320.

87. Bingley PJ, Mahon JL, Gale EA: Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). *Diabetes Care* 2008;31(1):146–150.
88. Ferrannini E, Mari A, Nofrate V, et al.: Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. *Diabetes* 2010;59(3):679–685.
89. Liu LL, Lawrence JM, Davis C, et al.: Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. *Pediatric Diabetes* 2010;11(1):4–11.
90. Brooks-Worrell B, Palmer JP: Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. *Clinical and Experimental Immunology* 2012;167(1):40–46.
91. Oresic M, Simell S, Sysi-Aho M, et al.: Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. *Journal of Experimental Medicine* 2008;205(13):2975–2984.
92. Pflueger M, Seppanen-Laakso T, Suortti T, et al.: Age- and islet autoimmunity-associated differences in amino acid and lipid metabolites in children at risk for type 1 diabetes. *Diabetes* 2011;60(11):2740–2747.
93. Santin I, Moore F, Colli ML, et al.: PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic beta-cell apoptosis via regulation of the BH3-only protein Bim. *Diabetes* 2011;60(12):3279–3288.
94. Snell-Bergeon JK, West NA, Mayer-Davis EJ, et al.: Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH case-control study. *Journal of Clinical Endocrinology & Metabolism* 2010;95(6):2868–2876.
95. Alkanani AK, Rewers M, Dong F, et al.: Dysregulated toll-like receptor-induced Interleukin-1 β and Interleukin-6 responses in subjects at risk for the development of type 1 diabetes. *Diabetes* 2012 Oct;61(10): 2525–33. Epub 2012 Jun 29.
96. Liu SM, Lee DH, Sullivan JM, et al.: Differential IL-21 signaling in APCs leads to disparate Th17 differentiation in diabetes-susceptible NOD and diabetes-resistant NOD.Ldd3 mice. *Journal of Clinical Investigation* 2011;121(11):4303–4310.
97. Wang X, Jia S, Geoffrey R, et al.: Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. *Journal of Immunology* 2008;180(3):1929–1937.
98. Sarkar SA, Lee CE, Victorino F, et al.: Expression and regulation of chemokines in murine and human type 1 diabetes. *Diabetes* 2012;61(2):436–446.
99. Barthson J, Germano CM, Moore F, et al.: Cytokines tumor necrosis factor- α and interferon- γ induce pancreatic beta-cell apoptosis through STAT1-mediated Bim protein activation. *The Journal of Biological Chemistry* 2011;286(45):39632–39643.
100. Marthour I, Lopez XM, Lefkaditis D, et al.: Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. *Diabetologia* 2012;55(9):2417–2420.
101. Oikarinen M, Tauriainen S, Oikarinen S, et al.: Type 1 diabetes is associated with enterovirus infection in gut mucosa. *Diabetes* 2012;61(3):687–691.
102. Vaarala O: Is the origin of type 1 diabetes in the gut? *Immunology & Cell Biology* 2012;90(3):271–276.

103. Hummel S, Ziegler AG: Early determinants of type 1 diabetes: experience from the BABYDIAB and BABYDIET studies. *American Journal of Clinical Nutrition* 2011;94(6 Suppl): 1821S–1823S.
104. Hagopian WA, Erlich H, Lernmark A, et al.: The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421,000 infants. *Pediatric Diabetes* 2011;12(8):733–743.
105. Sosenko JM, Palmer JP, Greenbaum CJ, et al.: Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. *Diabetes Care* 2006;29(3):643–649.
106. Tsai EB, Sherry NA, Palmer JP, Herold KC: The rise and fall of insulin secretion in type 1 diabetes mellitus. *Diabetologia* 2006;49:261–270.
107. Greenbaum CJ, Anderson AM, Dolan LM, et al.: Preservation of beta-cell function in autoantibody-positive youth with diabetes. *Diabetes Care* 2009;32(10):1839–1844.
108. Greenbaum CJ, Beam CA, Boulware D, et al.: Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. *Diabetes* 2012;61(8):2066–2073.
109. Klinke DJ: Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. *PLoS ONE* 2008;3(1):e1374.
110. In't Veld P: Insulinitis in human type 1 diabetes: the quest for an elusive lesion. *Islets* 2011;3(4):131–138.
111. Gianani R, Campbell-Thompson M, Sarkar SA, et al.: Dimorphic histopathology of long-standing childhood-onset diabetes. *Diabetologia* 2010;53(4):690–698.
112. Akirav EM, Lebastchi J, Galvan EM, et al.: Detection of beta cell death in diabetes using differentially methylated circulating DNA. *PNAS* 2011;108(47):19018–19023.
113. Arifin DR, Bulte JW: Imaging of pancreatic islet cells. *Diabetes Metabolism Research and Reviews* 2011;27(8):761–766.